Identification of HER2-positive metastases in patients with HER2-negative primary breast cancer by using HER2-targeted (89)Zr-pertuzumab PET/CT Journal Article

   

Authors:	Ulaner, G. A.; Carrasquillo, J. A.; Riedl, C. C.; Yeh, R.; Hatzoglou, V.; Ross, D. S.; Jhaveri, K.; Chandarlapaty, S.; Hyman, D. M.; Zeglis, B. M.; Lyashchenko, S. K.; Lewis, J. S.
Article Title:	Identification of HER2-positive metastases in patients with HER2-negative primary breast cancer by using HER2-targeted (89)Zr-pertuzumab PET/CT
Abstract:	Background Human epidermal growth factor receptor 2 (HER2)-targeted therapies are successful in patients with HER2-positive malignancies; however, spatial and temporal heterogeneity of HER2 expression may prevent identification of optimal patients for these therapies. Purpose To determine whether imaging with the HER2-targeted PET tracer zirconium 89 (89Zr)-pertuzumab can depict HER2-positive metastases in women with HER2-negative primary breast cancer. Materials and Methods From January to June 2019, women with biopsy-proven HER2-negative primary breast cancer and biopsy-proven metastatic disease were enrolled in a prospective clinical trial (ClinicalTrials.gov NCT02286843) and underwent 89Zr-pertuzumab PET/CT for noninvasive whole-biopsy evaluation of potential HER2-positive metastases. 89Zr-pertuzumab-avid foci that were suspicious for HER2-positive metastases were tissue sampled and examined by pathologic analysis to document HER2 status. Results Twenty-four women (mean age, 55 years ± 11 [standard deviation]) with HER2-negative primary breast cancer were enrolled. Six women demonstrated foci at 89Zr-pertuzumab PET/CT that were suspicious for HER2-positive disease. Of these six women, three had biopsy-proven HER2-positive metastases, two had pathologic findings that demonstrated HER2-negative disease, and one had a fine-needle aspirate with inconclusive results. Conclusion Human epidermal growth factor receptor 2 (HER2)-targeted imaging with zirconium 89-pertuzumab PET/CT was successful in detecting HER2-positive metastases in women with HER2-negative primary breast cancer. This demonstrates the ability of targeted imaging to identify patients for targeted therapies that might not otherwise be considered. © RSNA, 2020 Online supplemental material is available for this article. See the editorial by Mankoff and Pantel in this issue.
Journal Title:	Radiology
Volume:	296
Issue:	2
ISSN:	0033-8419
Publisher:	Radiological Society of North America, Inc.
Date Published:	2020-08-01
Start Page:	370
End Page:	378
Language:	English
DOI:	10.1148/radiol.2020192828
PUBMED:	32515679
PROVIDER:	scopus
PMCID:	PMC7543717
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088493791&doi=10.1148%2fradiol.2020192828&partnerID=40&md5=9b602806f870403d435e5bbb1bfba971
Notes:	Article -- Export Date: 3 August 2020 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/168502